• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Pre-Market Session

    4/17/24 8:08:12 AM ET
    $BIMI
    $CHRO
    $CLNN
    $DTIL
    Other Pharmaceuticals
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BIMI alert in real time by email

    Gainers

    • INVO Bioscience (NASDAQ:INVO) shares increased by 93.4% to $1.47 during Wednesday's pre-market session. The market value of their outstanding shares is at $3.8 million. As per the press release, Q4 earnings came out yesterday.
    • Clene (NASDAQ:CLNN) shares moved upwards by 40.8% to $0.44. The market value of their outstanding shares is at $56.0 million.
    • Galera Therapeutics (NASDAQ:GRTX) shares moved upwards by 31.76% to $0.22. The market value of their outstanding shares is at $12.1 million.
    • Vanda Pharma (NASDAQ:VNDA) stock moved upwards by 26.91% to $5.14. The company's market cap stands at $295.7 million.
    • Chromocell Therapeutics (AMEX:CHRO) shares moved upwards by 23.62% to $2.25. The market value of their outstanding shares is at $12.9 million.
    • BIMI Intl Medical (NASDAQ:BIMI) shares moved upwards by 16.98% to $1.86. The company's market cap stands at $26.0 million.

    Losers

    • Sage Therapeutics (NASDAQ:SAGE) stock decreased by 19.4% to $12.6 during Wednesday's pre-market session. The market value of their outstanding shares is at $757.3 million.
    • Ontrak (NASDAQ:OTRK) stock declined by 17.81% to $0.38. The company's market cap stands at $16.0 million. The company's, Q4 earnings came out yesterday.
    • China SXT Pharmaceuticals (NASDAQ:SXTC) shares declined by 17.29% to $1.34.
    • Dynatronics (NASDAQ:DYNT) shares decreased by 11.91% to $0.48. The company's market cap stands at $2.3 million.
    • Etao International Co (NASDAQ:ETAO) shares declined by 11.89% to $3.3. The market value of their outstanding shares is at $16.9 million.
    • Precision BioSciences (NASDAQ:DTIL) shares declined by 10.96% to $11.46. The market value of their outstanding shares is at $79.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BIMI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BIMI
    $CHRO
    $CLNN
    $DTIL

    CompanyDatePrice TargetRatingAnalyst
    Vanda Pharmaceuticals Inc.
    $VNDA
    3/5/2026$18.00Buy
    Truist
    Vanda Pharmaceuticals Inc.
    $VNDA
    11/5/2025$11.00Buy
    B. Riley Securities
    Sage Therapeutics Inc.
    $SAGE
    3/11/2025$5.00Underperform
    BofA Securities
    Precision BioSciences Inc.
    $DTIL
    1/10/2025$34.00Market Perform → Outperform
    BMO Capital Markets
    Sage Therapeutics Inc.
    $SAGE
    11/21/2024$4.00Underperform → Sector Perform
    RBC Capital Mkts
    Vanda Pharmaceuticals Inc.
    $VNDA
    10/31/2024$18.00Buy
    H.C. Wainwright
    Sage Therapeutics Inc.
    $SAGE
    10/10/2024Mkt Perform
    Raymond James
    Sage Therapeutics Inc.
    $SAGE
    10/4/2024$10.00 → $4.00Outperform → Sector Perform
    RBC Capital Mkts
    More analyst ratings

    $BIMI
    $CHRO
    $CLNN
    $DTIL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP & General Counsel Williams Timothy sold $350,755 worth of shares (42,434 units at $8.27), decreasing direct ownership by 10% to 377,450 units (SEC Form 4)

    4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)

    3/4/26 6:54:11 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, CFO & Treasurer Moran Kevin Patrick sold $350,821 worth of shares (42,442 units at $8.27), decreasing direct ownership by 9% to 411,380 units (SEC Form 4)

    4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)

    3/4/26 6:53:14 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, Chief Marketing Officer Wijkstrom Joakim sold $254,590 worth of shares (30,800 units at $8.27), decreasing direct ownership by 8% to 333,469 units (SEC Form 4)

    4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)

    3/4/26 6:52:29 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIMI
    $CHRO
    $CLNN
    $DTIL
    SEC Filings

    View All

    SEC Form 10-K filed by Galera Therapeutics Inc.

    10-K - Galera Therapeutics, Inc. (0001563577) (Filer)

    3/19/26 7:15:26 AM ET
    $GRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Precision BioSciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - PRECISION BIOSCIENCES INC (0001357874) (Filer)

    3/17/26 8:31:07 AM ET
    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by Clene Inc.

    10-K - Clene Inc. (0001822791) (Filer)

    3/17/26 7:00:40 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIMI
    $CHRO
    $CLNN
    $DTIL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Matlin David J bought $216,664 worth of shares (33,333 units at $6.50), increasing direct ownership by 7% to 477,824 units (SEC Form 4)

    4 - Clene Inc. (0001822791) (Issuer)

    1/13/26 2:48:54 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Germano Geno J bought $14,160 worth of shares (3,000 units at $4.72), increasing direct ownership by 14% to 23,883 units (SEC Form 4)

    4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)

    12/17/25 7:02:05 AM ET
    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Frankel Stanley bought $12,690 worth of shares (2,700 units at $4.70), increasing direct ownership by 16% to 19,478 units (SEC Form 4)

    4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)

    12/17/25 7:01:09 AM ET
    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIMI
    $CHRO
    $CLNN
    $DTIL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    China SXT Pharmaceuticals, Inc. Announces Share Re-classification

    TAIZHOU, China, March 23, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceutics, Inc. (NASDAQ:SXTC) (the "Company" or "SXTC"),  a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements ("TCMHS"), today announced that upon the market opening on March 24, 2026, the Company's Class A Ordinary Shares will be traded on The Nasdaq Stock Market under the symbol "SXTC". On July 28, 2025, the Company held a special meeting of shareholders (the "Meeting"). At the Meeting

    3/23/26 9:00:00 AM ET
    $SXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant Methods

    WASHINGTON, March 19, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA), a leader in innovative drug development and a vocal advocate for reducing unnecessary animal testing, today voiced serious concerns over the U.S. Food and Drug Administration (FDA)'s new draft guidance, "General Considerations for the Use of New Approach Methodologies in Drug Development," released March 18, 2026, by the Center for Drug Evaluation and Research (CDER). The FDA's draft guidance aims to support the use of New Approach Methodologies (NAMs)—advanced non-animal tools like in v

    3/19/26 4:34:00 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    iECURE Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of ECUR-506 Ahead of Planned BLA Submission

    FDA Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) program supports manufacturing readiness for therapies with expedited clinical development timelines ECUR-506 selected as one of up to nine programs annually Participation enables additional FDA engagement on CMC strategy ahead of a potential BLA submission iECURE, Inc., a clinical-stage genome editing company developing variant-agnostic in vivo targeted gene insertion therapies for the treatment of severe, inherited, neurometabolic disorders, today announced that the U.S. Food and Drug Administration (FDA) has selected ECUR-506, the company's investigational in vivo targeted gene insertion therapy

    3/18/26 8:00:00 AM ET
    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIMI
    $CHRO
    $CLNN
    $DTIL
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for PONVORY issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-6) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

    6/17/24 12:07:18 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for PONVORY issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-5) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

    6/17/24 12:07:18 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for FANAPT issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug FANAPT (SUPPL-23) with active ingredient ILOPERIDONE has changed to 'Approval' on 04/02/2024. Application Category: NDA, Application Number: 022192, Application Classification: Efficacy

    4/3/24 4:12:36 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIMI
    $CHRO
    $CLNN
    $DTIL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Truist initiated coverage on Vanda Pharma with a new price target

    Truist initiated coverage of Vanda Pharma with a rating of Buy and set a new price target of $18.00

    3/5/26 8:32:16 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    B. Riley Securities initiated coverage on Vanda Pharma with a new price target

    B. Riley Securities initiated coverage of Vanda Pharma with a rating of Buy and set a new price target of $11.00

    11/5/25 7:30:12 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BofA Securities resumed coverage on SAGE Therapeutics with a new price target

    BofA Securities resumed coverage of SAGE Therapeutics with a rating of Underperform and set a new price target of $5.00

    3/11/25 7:43:31 AM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIMI
    $CHRO
    $CLNN
    $DTIL
    Leadership Updates

    Live Leadership Updates

    View All

    Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement

    The combined company plans to launch ZELSUVMI™ for the treatment of molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, the combined company closed on a $50.1 million equity private placement Combined company will operate under the name "Pelthos Therapeutics Inc." and will trade on the NYSE American exchange under the ticker symbol "PTHS" starting on July 2, 2025 DURHAM, N.C., July 02, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc., a biopharmaceutical company committed to commercializing innovative therapeutic products for high unmet patient needs, today announced the closing of the previously announced merger agreement pursuant to which CHRO Me

    7/2/25 7:00:00 AM ET
    $CHRO
    $LGND
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary

    FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced the appointment of Anne Marie Cook, J.D., as Chief Legal Officer and Corporate Secretary. Ms. Cook is an accomplished pharmaceutical legal executive with a proven track record advising pharmaceutical companies and broad expertise in corporate governance, commercial law, regulatory compliance, strategic transactions and legal strategy. Ms. Cook most recently served as Senior Vice President, General Counsel of Sage Therapeutics, Inc. and previously se

    6/23/25 7:59:57 AM ET
    $PHAT
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sage Therapeutics Announces R&D Leadership Transition

    Sage Therapeutics, Inc. (NASDAQ:SAGE) today announced that Dr. Laura Gault, Chief Medical Officer, has decided to pursue a new opportunity and will depart the Company, effective March 21, 2025. Dr. Gault joined Sage Therapeutics in November 2022 and has led the Company's product pipeline through all stages of development. Mike Quirk, Chief Scientific Officer, will assume key responsibilities, including strategic guidance for clinical development programs, on an interim basis. "I would like to extend my sincerest gratitude to Laura for her leadership and dedication to advancing innovation for patients with debilitating brain health conditions," said Barry Greene, Chief Executive Officer of

    3/4/25 4:15:00 PM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIMI
    $CHRO
    $CLNN
    $DTIL
    Financials

    Live finance-specific insights

    View All

    Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026

    Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will publish financial results for the fourth quarter 2025 and provide a business update on March 12, 2026. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other gene editing technologies in the way it cuts, its smaller size, and its simpler structure. These features are intended for ARCUS nucleases

    3/9/26 4:15:00 PM ET
    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

    Full year 2025 Fanapt® net product sales increased by 24% to $117.3 million compared to full year 2024Full year 2025 total revenues increased by 9% to $216.1 million compared to full year 2024NEREUS™ (tradipitant) approved for the prevention of vomiting induced by motionBysanti™ (milsaperidone) NDA for bipolar I disorder and schizophrenia under review by the FDA; PDUFA target action date of February 21, 2026WASHINGTON, Feb. 11, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced financial and operational results for the fourth quarter and full year ended December 31, 2025.

    2/11/26 4:01:00 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026

    Conference Call and Webcast to Follow WASHINGTON, Feb. 4, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced it will release results for the fourth quarter and full year 2025 on Wednesday, February 11, 2026, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, February 11, 2026, during which management will discuss the fourth quarter and full year 2025 financial results and other corporate activities. To participate in the conference call, please dial 1-888-596-4144 (domestic) or 1-646-968-2525 (international

    2/4/26 6:01:00 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIMI
    $CHRO
    $CLNN
    $DTIL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sage Therapeutics Inc.

    SC 13G/A - Sage Therapeutics, Inc. (0001597553) (Subject)

    11/14/24 6:14:58 PM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Precision BioSciences Inc.

    SC 13G/A - PRECISION BIOSCIENCES INC (0001357874) (Subject)

    11/14/24 4:50:29 PM ET
    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ontrak Inc.

    SC 13G/A - Ontrak, Inc. (0001136174) (Subject)

    11/14/24 4:24:03 PM ET
    $OTRK
    Misc Health and Biotechnology Services
    Health Care